Vanguard Group Inc. Acquires 448,554 Shares of AbbVie Inc. $ABBV

Vanguard Group Inc. boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 0.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 177,747,261 shares of the company’s stock after buying an additional 448,554 shares during the quarter. AbbVie makes up approximately 0.6% of Vanguard Group Inc.’s investment portfolio, making the stock its 20th biggest holding. Vanguard Group Inc. owned about 10.06% of AbbVie worth $41,155,601,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of ABBV. Geode Capital Management LLC raised its position in shares of AbbVie by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after acquiring an additional 924,761 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in AbbVie by 6.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after purchasing an additional 1,517,222 shares during the last quarter. Norges Bank bought a new position in AbbVie in the second quarter worth about $4,288,200,000. Raymond James Financial Inc. lifted its position in shares of AbbVie by 41.8% during the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after buying an additional 2,753,312 shares during the last quarter. Finally, Amundi boosted its holdings in shares of AbbVie by 36.6% in the 2nd quarter. Amundi now owns 9,093,696 shares of the company’s stock valued at $1,734,623,000 after buying an additional 2,435,372 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

Analyst Ratings Changes

ABBV has been the subject of a number of analyst reports. Morgan Stanley increased their target price on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. BMO Capital Markets reissued an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a research report on Thursday, January 15th. Scotiabank initiated coverage on AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price on the stock. HSBC raised AbbVie from a “hold” rating to a “buy” rating and raised their price target for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Finally, DZ Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a report on Tuesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $251.00.

AbbVie Stock Up 1.8%

Shares of NYSE:ABBV opened at $231.57 on Monday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The stock has a market cap of $409.28 billion, a price-to-earnings ratio of 98.12, a PEG ratio of 0.81 and a beta of 0.35. The business has a 50-day moving average price of $223.56 and a 200-day moving average price of $221.07.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the prior year, the firm earned $2.16 earnings per share. AbbVie’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.